Drug (including placebo)
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Supratentorial Newly Diagnosed Inoperable Gliobastoma
Conditions
Supratentorial Newly Diagnosed Inoperable Gliobastoma
Trial Timeline
Aug 1, 2012 → Feb 1, 2013
NCT ID
NCT01558687About Drug (including placebo)
Drug (including placebo) is a phase 1 stage product being developed by Merck for Supratentorial Newly Diagnosed Inoperable Gliobastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01558687. Target conditions include Supratentorial Newly Diagnosed Inoperable Gliobastoma.
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01558687 | Phase 1 | Terminated |
Competing Products
2 competing products in Supratentorial Newly Diagnosed Inoperable Gliobastoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gliadel Wafer + Temozolomide | Eisai | Phase 2 | 31 |
| STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. + Spironolactone (drug) | Lantern Pharma | Phase 1/2 | 29 |